10-Q: Karyopharm Secures $36M, Addresses Going Concern in Q3

Karyopharm Therapeutics Inc. reported a net loss of $93.8 million for the nine months ended September 30, 2025, but secured $36 million in new financing and debt deferrals in October 2025 to address substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $33.1 million for the three months ended September 30, 2025, a 3% increase from $32.1 million in the prior year period.
• Reported a net loss of $93.8 million for the nine months ended September 30, 2025, a significant increase from $45.6 million in the prior year period.
• Total revenue for Q3 2025 increased by 14% to $44.0 million, driven by a 9% increase in net product revenue to $32.0 million and a 30% increase in license and other revenue to $12.0 million.
• Total revenue for the nine months ended September 30, 2025, decreased by 2% to $112.0 million, with net product revenue decreasing by 1% to $82.8 million and license and other revenue decreasing by 6% to $29.2 million.
• Operating loss improved by 42% for Q3 2025 to $(15.2) million and by 17% for the nine months ended September 30, 2025, to $(72.9) million, primarily due to reduced R&D and SG&A expenses.
• Cash, cash equivalents, and investments totaled $45.9 million as of September 30, 2025, down from $108.7 million at December 31, 2024.
• Accumulated deficit reached $1.7 billion as of September 30, 2025.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern within one year from the filing date.
• In October 2025, the company completed financing transactions totaling $27.5 million in new borrowings, $25.4 million in near-term deferrals of interest and royalty payments, and a private placement raising $8.8 million in gross proceeds.
• The October 2025 financing also included exchanges of $15.0 million of 2029 Notes and $24.3 million of 2025 Notes for common stock and warrants, and a temporary reduction in the minimum liquidity covenant.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a substantial accumulated deficit and explicit doubt about its ability to continue as a going concern. While recent financing provides a temporary lifeline and clinical trials are progressing, the underlying financial instability and the need for continuous capital raises indicate a high-risk profile.

Positives

• Operating loss for the three months ended September 30, 2025, improved by 42% to $(15.2) million compared to $(26.3) million in the prior year.
• Operating loss for the nine months ended September 30, 2025, improved by 17% to $(72.9) million compared to $(88.2) million in the prior year.
• Total revenue for the three months ended September 30, 2025, increased by 14% to $44.0 million, driven by a 9% increase in net product revenue and a 30% increase in license and other revenue.
• Research and development expenses decreased by 15% for Q3 2025 and 11% for YTD 2025, reflecting reduced scope in the multiple myeloma trial and cost reduction initiatives.
• Selling, general and administrative expenses decreased by 4% for Q3 2025 and 7% for YTD 2025 due to cost reduction initiatives.
• Net cash used in operating activities decreased by $38.1 million for the nine months ended September 30, 2025, compared to the prior year, primarily due to working capital changes from cost reduction initiatives.
• Completed enrollment in the Phase 3 SENTRY trial for myelofibrosis in September 2025, with top-line data expected in March 2026.
• Successfully executed a series of financing transactions in October 2025, including $27.5 million in new borrowings, $25.4 million in deferred payments, and an $8.8 million private placement, providing additional working capital and financial flexibility.

Negatives

• Net loss for the nine months ended September 30, 2025, significantly increased by over 100% to $93.8 million from $45.6 million in the prior year period.
• Accumulated deficit reached $1.7 billion as of September 30, 2025, indicating substantial historical losses.
• Cash, cash equivalents, and investments decreased to $45.9 million as of September 30, 2025, from $108.7 million at December 31, 2024.
• Substantial doubt exists regarding the company's ability to continue as a going concern within one year.
• Total revenue for the nine months ended September 30, 2025, decreased by 2% compared to the prior year.
• Interest income decreased significantly for both the three and nine months ended September 30, 2025, due to reduced investment balances.
• Other (expense) income, net, turned into a significant expense for Q3 and YTD 2025, primarily due to non-cash remeasurement of embedded derivatives and liability-classified common stock warrants, contrasting with a large gain in the prior year.
• The product return reserve increased in Q1 2025 due to atypical returns of expired XPOVIO units, negatively impacting net product revenue for the nine-month period.
• The eltanexor program remains on hold since January 2024, indicating a reduction in pipeline diversity.

Risks

• Substantial doubt about the ability to continue as a going concern due to significant operating losses and dependence on additional funding or strategic alternatives.
• Inability to raise sufficient additional funding or enter into strategic alternatives on acceptable terms could force delays, reductions, or elimination of research and development programs or commercialization efforts.
• Indebtedness, including the Amended Term Loan, Convertible Notes, and Amended Revenue Interest Agreement, could limit cash flow, expose the company to risks, and impair its ability to satisfy obligations.
• The company's business is substantially dependent on the commercial success of XPOVIO, and failure to achieve widespread market acceptance could materially harm the business.
• Substantial competition in the cancer treatment market from major pharmaceutical and biotechnology companies, including new novel therapeutics for multiple myeloma, could negatively impact product revenues.
• Clinical development is a lengthy, expensive, and uncertain process, with potential for delays or failures to demonstrate safety and effectiveness, as seen with expected delays in the EC-042 trial due to screen failure rates and new EU IVDR regulations.
• Serious adverse or unacceptable side effects related to XPOVIO or product candidates could delay or prevent regulatory approval, limit commercial value, or result in significant negative financial consequences.
• Interim or top-line clinical trial data may be subject to change or qualification based on complete analyses, and may not be predictive of final results.
• Failure to obtain and maintain patent protection for products or product candidates, or if the scope of protection is not sufficiently broad, could allow competitors to commercialize similar drugs.
• Exposure to product liability lawsuits related to XPOVIO commercialization and clinical trials could divert resources and incur substantial liabilities.
• Changes in U.S. and international trade policies, including potential restrictions on Chinese biotechnology companies (e.g., WuXi AppTec, WuXi Biologics) due to legislation like the BIOSECURE Act, could disrupt supply chains and increase costs.
• The company is subject to stringent privacy laws (HIPAA, CCPA, CPRA, GDPR) and information security risks, with non-compliance potentially leading to significant fines and penalties.
• Failure to maintain compliance with Nasdaq's continued listing requirements, such as the minimum bid price, could result in delisting and adversely affect stock liquidity and capital raising ability.
• The substantial number of outstanding warrants to purchase common stock could result in significant dilution to existing stockholders and adversely affect the trading price of common stock.

Future Outlook

The company expects to report top-line data from the Phase 3 SENTRY trial in myelofibrosis in March 2026. Top-line data from all patients in the 60 mg cohort of the Phase 2 SENTRY-2 trial with at least 24 weeks of follow-up is expected in 2026. Top-line data from the event-driven Phase 3 XPORT-EC-042 trial in endometrial cancer is anticipated in mid-2026. Net product revenue in the fourth quarter of 2025 is expected to be consistent with the third quarter of 2025, while license and other revenue is expected to decrease in Q4 2025 due to lower expected milestone revenue and full recognition of Menarini reimbursement revenue in Q3. Research and development and selling, general and administrative expenses are expected to remain relatively consistent in Q4 2025.

Management Comments

• Our continued operations are dependent on our ability to raise additional funding or enter in other strategic alternatives and marketing XPOVIO in its currently approved indications.
• We plan to address the conditions that raise substantial doubt regarding our ability to continue as a going concern by, among other things, obtaining additional funding through equity offerings, debt financings and refinancings, collaborations, strategic alliances and/or licensing arrangements.
• We reduced our workforce by approximately 20% as part of our ongoing careful management of operating expenses (July 11, 2025 announcement).
• We currently expect that our existing cash, cash equivalents and investments as well as cash flows from net product revenue and license and other revenue, will enable us to fund our current operating plans into the second quarter of 2026.

Industry Context

The oncology market, particularly for multiple myeloma and endometrial cancer, is highly competitive and rapidly evolving. In multiple myeloma, new bispecific T-cell engagers (TECVAYLI, ELREXFIO, TALVEY) and CAR T-cell therapies (CARVYKTI, Abecma) have recently been approved or expanded into earlier lines of therapy, intensifying competition for XPOVIO. The approval of BLENREP in combination with bortezomib and dexamethasone further adds to the competitive landscape. In endometrial cancer, the treatment landscape has evolved with the approval of checkpoint inhibitors (dostarlimab-gxly, pembrolizumab, durvalumab), which impacts the regulatory pathway and potential approvability of new therapies like selinexor.

Comparison to Industry Standards

• In multiple myeloma, Karyopharm's XPOVIO competes with recently approved bispecific T-cell engagers such as TECVAYLI (teclistamab-cqyv), ELREXFIO (elranatamab-bcmm), and TALVEY (talquetamab-tgvs), as well as CAR T-cell therapies like CARVYKTI (ciltacabtagene autoleucel) and Abecma (idecabtagene vicleucel). These newer therapies represent significant advancements and could impact XPOVIO's market share, especially as they move into earlier lines of therapy.
• The approval of BLENREP (belantamab mafodotin) in combination with bortezomib and dexamethasone in October 2025 further intensifies competition in the multiple myeloma space, offering another treatment option for patients.
• For endometrial cancer, the evolving treatment landscape includes checkpoint inhibitors such as dostarlimab-gxly, pembrolizumab, and durvalumab. These approvals set a higher bar for new therapies and influence the FDA's assessment of clinical trial designs and approvability criteria, as noted by the FDA's feedback on Karyopharm's EC-042 trial.

Management Changes

Corporate Governance

Legal Proceedings

• Potential for litigation and damages by competitors under the CREATES Act if the company is claimed not to be providing sufficient quantities of approved products for testing in support of ANDAs and 505(b)(2) applications.
• Exposure to product liability lawsuits related to the commercialization of XPOVIO and the testing of product candidates in human clinical trials.
• Ongoing legal challenges to FDA approvals, such as the mifepristone litigation, could impact the ability to develop new drug product candidates and maintain approval of existing ones.
• Potential for increased litigation and judicial scrutiny of regulatory policies following the U.S. Supreme Court's decision on agency deference.

Related Party Transactions

• KKR & Co. Inc. (successor in interest to HCRx) is a key related party, holding the Amended Term Loan, 2029 Notes, and the Amended Revenue Interest Agreement, with significant influence over the company's debt and royalty obligations.

Stakeholder Impact

• Shareholders face significant dilution from recent and potential future equity offerings and warrant exercises, as well as increased stock price volatility due to financial uncertainty and going concern issues.
• Employees have been impacted by workforce reductions (20% on July 11, 2025), which may affect morale and productivity.
• Creditors (lenders and noteholders) have increased security and oversight through the Amended Term Loan, New 2029 Notes, and Amended Revenue Interest Agreement, including a board observer, but still face risk given the going concern warning.
• Patients may experience delays in access to new therapies if clinical development programs are curtailed or delayed due to funding issues.

Next Steps

• Report top-line data from the Phase 3 SENTRY trial in myelofibrosis in March 2026.
• Report top-line data from all patients in the 60 mg cohort of the Phase 2 SENTRY-2 trial with at least 24 weeks of follow-up in 2026.
• Report top-line data from the event-driven Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026.
• Continue to seek additional funding through equity offerings, debt financings and refinancings, collaborations, strategic alliances, and/or licensing arrangements.
• Evaluate opportunities to raise additional funds through the 2023 Open Market Sale Agreement with Jefferies and in connection with reporting data from ongoing Phase 3 clinical trials.
• Comply with post-marketing commitments for XPOVIO's accelerated approvals in multiple myeloma and DLBCL.

Key Dates

Recommendation

While the company faces severe financial challenges, including a substantial accumulated deficit and an explicit going concern warning, the recent October 2025 financing transactions provide a temporary liquidity bridge and debt restructuring. The ongoing Phase 3 clinical trials for myelofibrosis and endometrial cancer represent significant pipeline catalysts with top-line data expected in 2026. For risk-tolerant investors, the potential for positive clinical readouts and the temporary financial stabilization could warrant holding, but the long-term viability remains highly dependent on successful clinical development, further capital raises, and achieving profitability, making it a speculative investment.

Keywords

Karyopharm, KPTI, XPOVIO, selinexor, oncology, multiple myeloma, myelofibrosis, endometrial cancer, pharmaceutical, biotechnology, SEC filing, 10-Q, financing, debt restructuring, going concern, clinical trials, drug development, corporate finance